Physician profile

Stuart Fischer

Cardiovascular Disease · Los Alamitos, CA

NPI 1083656086

$7,574.58

in general payments reported to CMS, 2019-2025

39 companies · $858 in 2025

The $858 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,179.12

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,328.30 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $1,049.33 2019-2025 Jardiance
Merck Sharp & Dohme LLC $552.24 2021-2025 Verquvo, Capvaxive, Steglatro
Amgen INC. $550.68 2019-2025 Repatha, Repatha
Janssen Pharmaceuticals, INC $549.52 2019-2024 Xarelto
Pfizer INC. $528.21 2019-2025
Amarin Pharma, INC. $271.84 2019-2021
Sanofi-Aventis U.S. LLC $231.61 2019-2024
Boston Scientific Corporation $209.87 2019-2025 Watchman Flx, Lux-Dx Insertable Cardiac Monitor
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $199.11 2019-2025 Lifevest
Atricure, INC. $161.63 2019-2024
Abiomed $157.41 2025
Irhythm Technologies, INC. $155.38 2019-2024 Zio Xt Patch, Zio Monitor
Scpharmaceuticals INC. $142.59 2023-2025
E.R. Squibb & Sons, L.L.C. $141.52 2022-2024 Camzyos
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Kestra Medical Technology Services, INC. $135.86 2022-2023 Assure Wcd
Kiniksa Pharmaceuticals International, Plc $134.13 2024 Arcalyst
Regeneron Healthcare Solutions, INC. $111.55 2019-2021
Heartflow, INC. $99.94 2022
Astrazeneca Pharmaceuticals Lp $97.96 2020-2025 Wainua
Alnylam Pharmaceuticals INC. $79.83 2019-2022
Bardy Diagnostics, INC. $74.52 2020-2021
Portola Pharmaceuticals, LLC $63.11 2019
Kiniksa Pharmaceuticals, Ltd. $60.36 2021-2023 Arcalyst
Impulse Dynamics (USA) INC. $59.01 2023 Optimizer
Novo Nordisk INC $56.09 2025 Ozempic
Medtronic Vascular, INC. $52.63 2019
Medtronic, INC. $46.58 2022-2023 Venaseal
Actelion Pharmaceuticals US, INC. $35.21 2024 Uptravi, Opsumit
Lundbeck LLC $33.99 2019-2020
Resmed Corp $30.03 2022
Abbott Laboratories $26.12 2025 Thoratec Heartmate 3 Lvas Implant Kit
Csl Behring $24.79 2020
Altathera Pharmaceuticals LLC $24.25 2025 Sotalol Hydrochloride
Bayer Healthcare Pharmaceuticals INC. $23.30 2021
Biosense Webster, INC. $23.01 2021
Inspire Medical Systems, INC. $20.38 2025 Inspire
Tactile Systems Technology INC $17.90 2024 Entre Plus, Flexitouch Plus
Esperion Therapeutics, INC. $14.79 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stuart Fischer

$7,574.58

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $858 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/230741/stuart-fischer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.